Get started
Author

Y. Tan

Observed names: May Tan, Y Tan, Ying Siow (May) Tan, Ying Siow Tan
ORCID: 0009-0001-5417-8088
Observed ORCID: 0009-0001-5417-8088
OpenAlex ID: A5040968372
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
2024 · Skye Montoya, Jessie Bourcier, et al. · Science · 169
PDF
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors
2026 · Quinlan Sievers, Hao Lu, et al. · Cancer Discovery · 3
Bexobrutideg: A Selective, Catalytic Degrader of Bruton’s Tyrosine Kinase Overcomes Inhibitor Resistance and Suppresses Autoantibody-Mediated Disease
2026 · Mark Noviski, Paul Auger, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
Abstract P3-10-23: RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer: APRIL Trial
2025 · Lei Lei, P. Fu, et al. · Clinical Cancer Research
10P Comparison of 28-gene and 70-gene panel in risk-prediction of Chinese women with early-stage HR-positive and HER2-negative breast cancer
2023 · L. Lei, W. Cao, et al. · Annals of Oncology
PDF
Abstract P3-06-03: Dual p38/NLK kinase inhibitor as potential novel therapeutic agent for tamoxifen-resistant luminal breast cancer
2018 · X Wang, X Cao, et al. · Cancer Research
Quantitative measurement of HER2 expression and HER2 homo-dimerization in formalin-fixed paraffin-embedded (FFPE) breast cancer tissues using a novel proximity-based assay
2007 · W. Huang, Y. Tan, et al. · Journal of Clinical Oncology
Works count: 7
Citation count: 173
H-index: 2
I10-index: 1
Year
Topic
Type